TCT TAVR and TMTT Investor Q&A - EDWARDS LIFESCIENCES CORP

Explicit Guidance:

• No financial guidance (revenue, earnings, capex, margins, or share count) for specific future periods (e.g., FY2024, FY2025, or FY2027) was provided in the transcript.
• Management indicated that specific timelines regarding indication expansion and reimbursement impacts will be detailed at the December Investor Conference, rather than in this session.

Business-Segment Outlook:

• TMTT (Tricuspid Mitral Tricuspid Transcatheter Therapy): The portfolio now includes a full complement of repair and replacement therapies for mitral and tricuspid disease in the U.S. (post-approval of TTVR/Evoque and Triclip). Management expects a continued acceleration in referrals as the "forgotten valve" gains traction, moving from identifying patients to active screening.
• TAVR (Transcatheter Aortic Valve Replacement): The PROGRESS trial results are expected to trigger a paradigm shift in practice, moving treatment from "watchful waiting" to active intervention for moderate aortic stenosis (AS) patients with at-risk features. This is anticipated to expand the addressable patient population significantly beyond the current severe AS indication.
• Pipeline: The "Activate" real-world analysis and PROGRESS data are expected to drive immediate screening initiatives, with the expectation that ~30-40% of patients currently labeled as "moderate" in community settings will be re-classified as "severe" or "at-risk" upon comprehensive valve clinic evaluation (CT/echo).

Market and Competitive Outlook:

• Adoption Curve: Management anticipates an immediate but gradual uptake in physician behavior, with a "flip" in the adoption curve as the PROGRESS data becomes widely disseminated. Physicians are expected to aggressively refer moderate AS patients for evaluation to avoid missing "at-risk" cohorts (80% of moderate AS patients in the real world possess at least one at-risk feature).
• Competitive Landscape: Edwards highlights its dual capability in both repair and replacement for tricuspid and mitral valves as a structural advantage, contrasting with competitors offering only one modality.
• Referral Dynamics: A significant shift is anticipated from general cardiology to specialized valve clinics, driven by the complexity of identifying risk features (AFib, low EF, symptoms) and the need for CT scans to confirm eligibility.

Macro / Industry Outlook:

• Cost-Effectiveness: Citing a late-breaking cost-effectiveness study (Neil Butala) on early TAVR (median 5-year follow-up), management notes that early intervention is strongly within the cost-effective range compared to current CMS-reimbursed therapies.
• Regulatory Environment: Management expresses high confidence that the FDA, having collaborated closely on the PROGRESS trial design, will extend the indication to moderate AS "with all due haste." They anticipate a potential reclassification from Class 2A to Class 1 indication if corroborative data emerges.
• Reimbursement: While no specific NCD changes were confirmed for this session, management notes that existing CMS language allows for "reasonable and necessary" applications, creating room for moderate AS coverage. They anticipate a favorable reimbursement outcome driven by the 52% reduction in heart failure hospitalizations and quality of life improvements.

Strategic Initiatives:

• Clinical Education: A major strategic focus is the "education of the field," specifically training physicians to recognize that moderate AS is "not a benign disease" and to move away from passive surveillance.
• Screening & Referral Pathways: Management plans to implement active screening programs to identify the "missed" population (moderate AS patients with risk features) who are currently under-diagnosed or misclassified.
• Evidence Generation: Continued investment in generating long-term data (5-year follow-ups) and real-world evidence to support the "continuum" approach to AS treatment, rather than the historical "moderate/severe" dichotomy.

Risks and Headwinds to Outlook:

• Guideline Lag: The primary risk is the delay between clinical data availability and the formal update of medical guidelines and CMS NCDs, which could slow the initial scale of reimbursement for moderate AS.
• Adoption Variance: While management expects high physician interest, the actual uptake depends on general cardiologists' willingness to refer patients, which may vary by region and practice structure.
• Under-Diagnosis: A persistent headwind is the current systemic failure to perform repeat echos or CT scans in the community, leading to the continued under-treatment of the disease despite new data.

Management Tone on the Future:

• Confidence: Extremely high. Management describes the PROGRESS results as a "turning point," a "revolution," and a "starting point" for redefining aortic stenosis management.
• Vision: The tone emphasizes moving from categorical classification (mild/moderate/severe) to a "continuum of human biology," where treatment is driven by clinical risk features rather than hemodynamic severity alone.
• Urgency: There is a strong sense of urgency to change clinical practice immediately, with management stating they will make practitioners "very uncomfortable" about the status quo of watching moderate AS patients.
• Impact: Management believes the data will empower physicians to make earlier interventions, fundamentally changing the natural history of the disease for a large, underserved patient population.

Miscellaneous:

• Patient Demographics: The PROGRESS trial population (78 years old, 55% high/intermediate risk) represents a large, real-world applicable cohort where 72% had at least two at-risk features.
• Safety Profile: The safety profile for TAVR in moderate AS (0% mortality, 0% disabling stroke at 30 days) is highlighted as superior to any prior TAVR population, comparable to the safety of a colonoscopy.
• Clinical Endpoints: The 52% reduction in heart failure hospitalizations is identified as the primary clinical driver, with a noted potential for mortality benefit to emerge in longer-term (5+ year) follow-up analyses.